WeVote
Log In

Bill

Bill

S 6466

Authorizes reimbursement for testing for familial dysautonomia, Canavan's disease and Tay-Sachs

2025 Regular Session Introduced by Cordell Cleare

Bill S 6466 mandates insurance reimbursement for testing familial dysautonomia, Canavan's disease, and Tay-Sachs, improving access for at-risk patients.

REFERRED TO INSURANCE
0
WeVote Research Nonpartisan
Bill Summary · S 6466

Summary of Bill S 6466

Bill Overview

Bill Number: S 6466
Title: Authorizes reimbursement for testing for familial dysautonomia, Canavan's disease, and Tay-Sachs
Status: Referred to Insurance
Introduced Date: March 14, 2025
Classification: Bill

Purpose and Intent

The primary purpose of Bill S 6466 is to ensure that individuals undergoing testing for specific genetic disorders—namely familial dysautonomia, Canavan's disease, and Tay-Sachs—are eligible for reimbursement through health insurance plans. This legislation aims to improve access to necessary genetic testing for these conditions, which are particularly relevant to certain populations, including those of Ashkenazi Jewish descent.

Key Provisions

  • Reimbursement Authorization: The bill mandates that health insurance providers cover the costs associated with testing for familial dysautonomia, Canavan's disease, and Tay-Sachs.
  • Scope of Coverage: The legislation specifies that the reimbursement applies to both diagnostic testing and carrier screening for these genetic disorders.
  • Insurance Plan Requirements: Insurance companies will be required to include these tests in their coverage plans, ensuring that patients do not face prohibitive out-of-pocket expenses for necessary testing.

Affected Parties

  • Patients: Individuals who are at risk for or have a family history of familial dysautonomia, Canavan's disease, or Tay-Sachs will benefit from reduced financial barriers to testing.
  • Healthcare Providers: Medical professionals who recommend or conduct these tests will see an increase in patient access to necessary genetic screenings.
  • Insurance Companies: Health insurers will need to adjust their policies and coverage plans to comply with the new reimbursement requirements.

Procedural Aspects

  • Current Status: As of March 14, 2025, the bill has been referred to the Insurance Committee for further consideration.
  • Related Legislation: This bill is related to several prior-session bills (A 299, A 4372, A 264, A 1134, A 4447, A 2667, A 2846, S 8572, S 2926) and has a companion bill (A 2476) that may address similar issues.

Conclusion

Bill S 6466 represents a significant step toward enhancing access to genetic testing for familial dysautonomia, Canavan's disease, and Tay-Sachs. By mandating insurance reimbursement for these tests, the legislation aims to alleviate financial burdens on patients and promote early detection and intervention for these genetic disorders. The bill is currently under review by the Insurance Committee, and its progress will be closely monitored by stakeholders in the healthcare community.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.